Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PRM-151 in myelofibrosis
NL-OMON44095Phase 2Active, not recruiting
- Sponsor
- Promedior
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zinpentraxin alfa in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (3 arms), sponsored by Promedior. Primary endpoint: Bone marrow response rate. Started Jun 2016; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NL-OMON44095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44095.